跳至主要内容
临床试验/jRCT2080222672
jRCT2080222672未知2 期

A Phase II, multi-center, randomized, double-blind study of T-4288 in patients with community-acquired pneumonia

Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)0 个研究点开始时间: 待定
适应症

试验速览

阶段
2 期
发起方
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Multi-center, Randomized, Double-Blind, Active-controlled study

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Age: 20 years of age and older
  • Gender : Both
  • Confirmed clear infiltrative shadow by chest X-ray or CT within 48 hours prior to the first administration of the study drug
  • Confirmed at least one of the following changes in laboratory values;
  • WBC increased (WBC > 10000 /mm3)
  • Stab cell > 15%
  • WBC decreased (WBC < 4500 /mm3)
  • Confirmed at least one of the following clinical symptoms and/or findings:
  • Abnormal findings on auscultation and/or percussion
  • Dyspnea or tachypnea

排除标准

  • Having improvement of clinical symptoms due to pneumonia by other systemic antibiotics
  • Having a history of allergy to macrolide or quinolone antibiotics

结局指标

主要结局

-

efficacy, safety and pharmacokinetic profile

次要结局

未报告次要终点

研究者

发起方
Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)

相似试验